Cargando…

1(st) World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy (PRRNT)

Detalles Bibliográficos
Autor principal:	Padhy, Ajit Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications Pvt Ltd 2011
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198042/

Ejemplares similares

1(st) World Congress on Ga-68 and Peptide Receptor Radionuclide Therapy (PRRNT), June 23–26, 2011, Zentralklinik Bad Berka, Germany
por: Baum, Richard P., et al.
Publicado: (2011)

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Zaknun, John J., et al.
Publicado: (2013)

Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Bodei, L., et al.
Publicado: (2013)

Abstracts of Poster Presentations (PRRNT)
Publicado: (2011)

Diagnosis of Men-I Syndrome on (68)Ga-DOTANOC PET-CT and Role of Peptide Receptor Radionuclide Therapy With (177)Lu-DOTATATE
por: kumar Gupta, Santosh, et al.
Publicado: (2012)

The Dependence of Renal (68)Ga[Ga]-DOTATOC Uptake on Kidney Function and Its Relevance for Peptide Receptor Radionuclide Therapy with (177)Lu[Lu]-DOTATOC
por: Gühne, Falk, et al.
Publicado: (2021)

Comparison of [(18)F]DOPA and [(68)Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy
por: Veenstra, Emile B., et al.
Publicado: (2022)

Preparation and Surface Characterization of Cerium Dioxide for Separation of (68)Ge/(68)Ga and Other Medicinal Radionuclides
por: Ondrák Fialová, Kateřina, et al.
Publicado: (2023)

Peptide Receptor Radionuclide Therapy
por: Hofland, Johannes, et al.
Publicado: (2022)

Prospective of (68)Ga Radionuclide Contribution to the Development of Imaging Agents for Infection and Inflammation
por: Velikyan, Irina
Publicado: (2018)

Characterization of SnO(2)-based (68)Ge/(68)Ga generators and (68)Ga-DOTATATE preparations: radionuclide purity, radiochemical yield and long-term constancy
por: Sudbrock, Ferdinand, et al.
Publicado: (2014)

Abstracts of Poster Presentations (Ga-68 Imaging)
Publicado: (2011)

Somatostatin Receptor Avidity in Gastrointestinal Stromal Tumors: Theranostic Implications of Gallium-68 Scan and Eligibility for Peptide Receptor Radionuclide Therapy
por: Loaiza-Bonilla, Arturo, et al.
Publicado: (2017)

Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT
por: Oh, Sowon, et al.
Publicado: (2011)

21st ESICM Annual Congress
Publicado: (2008)

21st ESICM Annual Congress
Publicado: (2008)

Peptide Receptor Radionuclide Therapy in Thyroid Cancer
por: Gubbi, Sriram, et al.
Publicado: (2022)

Dosimetric Considerations in Radioimmunotherapy and Systemic Radionuclide Therapies: A Review
por: Loke, Kelvin S. H., et al.
Publicado: (2011)

Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle
por: Nilica, Bernhard, et al.
Publicado: (2016)

Abstracts: 31(st)European Congress of Pathology
Publicado: (2019)

Abstracts from the World Congress of Cardiology/Brazilian Congress of Cardiology 2022
Publicado: (2023)

1st World Congress on Superconductivity
por: Burnham, Calvin G, et al.
Publicado: (1988)

21st IFAC World Congress
por: Findeisen, Rolf, et al.
Publicado: (2020)

The Current Role of Peptide Receptor Radionuclide Therapy in Meningiomas
por: Fodi, Christina-Katharina, et al.
Publicado: (2022)

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements
por: Merola, Elettra, et al.
Publicado: (2023)

World Molecular Imaging Congress 2022
Publicado: (2023)

THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience
por: Baum, Richard P., et al.
Publicado: (2012)

1st World Congress of the Bernouilli Society
Publicado: (1986)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor
por: Häfliger, Simon, et al.
Publicado: (2020)

Peptide Receptor Radionuclide Therapy and Primary Brain Tumors: An Overview
por: Cimini, Andrea, et al.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward
por: Feijtel, Danny, et al.
Publicado: (2020)

The Effects of Peptide Receptor Radionuclide Therapy on the Neoplastic and Normal Pituitary
por: Marques, Pedro
Publicado: (2023)

21st Brazilian Diabetes Society Congress
Publicado: (2018)

Research Communications of the 31(st) ECVIM‐CA Online Congress
Publicado: (2021)

Cyclotron-based production of (68)Ga, [(68)Ga]GaCl(3), and [(68)Ga]Ga-PSMA-11 from a liquid target
por: Rodnick, Melissa E., et al.
Publicado: (2020)

21st ESICM Annual Congress
Publicado: (2008)

Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study
por: Ebbers, Sander C., et al.
Publicado: (2021)

25th IFSO World Congress Silver Anniversary
por: Ferrell, Ashley
Publicado: (2022)

1(st) International One Health Congress Abstracts: Plenary Abstracts
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_2vrke5dnc4c8fcbcf0behmn9d4